BlinkLab

Study with Columbia University on Spinocerebellar Ataxias

Partnership aligns with BlinkLab’s strategy to enhance its AI-powered digital platform for sensory phenotyping and promote global adoption.

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI-powered diagnostic tests for neurological disorders, advises it will be participating in a clinical study in patients with spinocerebellar ataxias conducted by Columbia University, New York.


Highlights

  • New study in partnership with Columbia University, New York, to study the effect of aerobic physical exercise on neuroplasticity in adults with spinocerebellar ataxias (“SCA”).
  • Potential to demonstrate that the BlinkLab eyeblink conditioning test can serve as an effective biomarker for neuroplasticity in human SCA patients.
  • Partnership will contribute to global adoption of the BlinkLab platform by world renowned centres and research institutions to study a variety of neurological disorders.
  • Study will continue for up to 18 months and will recruit up to 62 adults with SCA.
  • Collaboration agreement ensures that BlinkLab will have an option to exclusively licence any intellectual property developed as a direct result of the partnership.
Henk-Jan Boele, CEO of BlinkLab commented:

“Since the very first successful test of the BlinkLab platform in the lab at Princeton University, our team’s vision has always been to develop a tool that will someday be considered as a standard of care in the initial diagnosis of neurodevelopmental conditions where children have difficulties in processing sensory information, such as autism and ADHD. However, as a team of scientists we also envisioned the development of a research platform that would facilitate groundbreaking digital sensory phenotyping in neuropsychiatric conditions in a much broader sense. In the past few months we have made significant progress towards this goal as evident from the adoption rate of our technology among top researchers across a broad range of neuropsychiatric clinical disciplines. We know that research adoption will smoothen clinical adoption. Data generated from these studies will further inform our machine learning training and ensure BlinkLab remains the leader in the field of digital sensory phenotyping in humans.”

What is Spinocerebellar Ataxia?

Spinocerebellar ataxias are a group of disorders in which progressive cerebellar degeneration leads to severe disability and even death. An estimated 150,000 Americans are living with these diseases1, and the average annual healthcare cost to the United States is over 1.9 billion dollars2. There are currently no effective treatments or cures for genetic causes of these diseases. Thus, there is a critical need to find treatments that slow disease progression and allow affected individuals to live more functional lives.

Researchers at Columbia University Medical Center demonstrated that aerobic training is a promising treatment for spinocerebellar ataxias, but the mechanism of action is not fully understood. Training may increase leg strength and endurance which allow compensation for balance deficits, but may also cause neuroplastic changes in the brain that are of benefit. In fact, long-term aerobic training in healthy individuals has been shown to create a fertile brain environment by increasing expression of plasticity-related genes and growth factors to support subsequent learning.

Prior work with in-person laboratory assessments has shown that individuals with spinocerebellar ataxia have impaired eyeblink conditioning, poor retention of learning, and difficulty increasing learning capacity across multiple training sessions. There are no published studies in humans examining the impact of exercise training on eyeblink conditioning, but a few animal studies have been conducted. Experimental animals that perform aerobic exercise are able to condition (i.e. associative learning tasks) significantly better than sedentary rats.

Dr. Scott Barbuto, Columbia University, commented on the study:

”The current study will investigate the impact of acute and long-term aerobic training on eyeblink conditioning in individuals with spinocerebellar ataxia. The aim of this study is to demonstrate that aerobic training, but not balance training, causes neuroplastic changes in the cerebellum to enhance motor learning. Eyeblink conditioning has had limited use in clinical studies and is used more often in basic science research. Reasons for limited use include: the high cost of the standard equipment setup needed to test eyeblink conditioning and the need for extensive programming and data management skills to acquire and interpret data. Some studies have been conducted on individuals with spinocerebellar ataxia, but sample sizes are typically very small, ranging from 8-24 participants. With the use of BlinkLab, we will be able to test many individuals with ataxia and determine if differences exist between various types. We will also determine if exercise impacts eyeblink conditioning in individuals with ataxia, a topic that has not been investigated to date.”


Click here for the full ASX Release

This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BB1:AU
BlinkLab Limited

BlinkLab Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
BlinkLab Limited

BlinkLab Limited


Keep reading...Show less
AI visualization.

Tech 5: AI Takes Center Stage at CES, NVIDIA Unveils Cosmos Platform

Global markets were turbulent this week on speculation about US President-elect Donald Trump's trade policies.

Initial gains on Monday (January 6), driven by rumors of less aggressive tariffs, were followed by a mixed performance as the Consumer Electronics Show (CES) kicked off in Las Vegas, Nevada, and investors awaited key economic data.

Keep up with the latest developments in the world of tech with the Investing News Network.

Keep reading...Show less
A microchip with a US flag.

Micron to Expand in Singapore with US$7 Billion AI Chip-packaging Facility

Micron Technology (NASDAQ:MU) announced a US$7 billion investment to build a high-bandwidth memory (HBM) chip-packaging facility in Singapore to meet rising global demand for artificial intelligence (AI) technology.

The facility, which will be adjacent to the US-based semiconductor manufacturer's existing manufacturing site in Singapore, broke ground this week and is scheduled to begin operations by 2026.

Designed to enhance the company’s advanced chip-packaging capabilities, the plant is expected to create 1,400 jobs initially, with the potential to generate up to 3,000 positions as operations scale by 2027.

Keep reading...Show less
BlinkLab

Positive Outcome from FDA Pre-Submission Meeting

BlinkLab Achieves Pivotal Step Towards FDA Approval for Autism Diagnostic App

BlinkLab Limited (ASX:BB1) (“BlinkLab”, or the “Company”), an innovative digital healthcare company is pleased to announce a positive outcome from its Pre-Submission meeting with the FDA yesterday. The FDA has confirmed the study design and data requirements in order to achieve 510(k) clearance and subsequently launch the diagnostic app in the U.S. The Company plans to complete both programs within 12-16 months after the necessary approvals and site engagements have been secured.

Keep reading...Show less
Man at laptop with AI symbols superimposed.

AI Market Forecast: Top Trends for AI in 2025

The United Nations has designated 2025 as the year of quantum science and technology, highlighting the profound impact that technological advancements are poised to have on the world.

The increasing prevalence of artificial intelligence (AI) across a wide array of industries has spurred significant investment in the sector over the last two years as the world's largest tech firms jump in. As AI continues to evolve, many investors are wondering if 2025 will be a pivotal year when these investments begin to show significant returns.

From its impact on stock market valuations to its transformative potential across industries, here the Investing News Network delves into the key trends and developments that are shaping the future of AI.

Keep reading...Show less
Rocketboots Limited

RocketBoots Limited (ASX: ROC) – Reinstatement to Quotation

Description

The suspension of trading in the securities of RocketBoots Limited (‘ROC’) will be lifted immediately following the release by ROC of an announcement regarding the details of the capital raise, board changes and remuneration updates.

Keep reading...Show less
Rocketboots Limited

RocketBoots Successfully Completes Capital Raise and Board Changes; Positioned to Deliver International Expansion in 2025

Artificial Intelligence software company RocketBoots Limited (ASX:ROC) (RocketBoots or the Company), is pleased to announce the appointment of Mr Roy McKelvie as Chairman, to guide the company through a period of material scaling. Mr McKelvie will invest $200k in RocketBoots, subject to shareholder approval, and cornerstone a raise for $500k at $0.085 per share (before costs) with other sophisticated investors (Placement).

Keep reading...Show less
BlinkLab Limited

BlinkLab Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×